Omada Health (OMDA) reported $260M in revenue for fiscal 2025, +53.2% year on year. That ranks #2557 by revenue among 2853 SEC filers and #263 in Healthcare. It posted a net loss of −$12.8M for the same year. Revenue has grown 45.6% a year on average since 2023 ($123M then). The fiscal 2025 balance sheet shows $305M in total assets, $222M in cash and $0 in long-term debt.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $260M | +53.2% | FY20252025-12-31 |
| Gross profitGrossProfit | $171M | +66.2% | FY20252025-12-31 |
| Operating incomeOperatingIncomeLoss | −$12.0M | +$31.7M | FY20252025-12-31 |
| Net incomeNetIncomeLoss | −$12.8M | +$34.4M | FY20252025-12-31 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | $18.3M | +$52.4M | FY20252025-12-31 |
| Capital expenditurePaymentsToAcquirePropertyPlantAndEquipment | $1.3M | +121.8% | FY20252025-12-31 |
| Total assetsAssets | $305M | +102.4% | FY20252025-12-31 |
| Shareholders' equityStockholdersEquity | $230M | +$614M | FY20252025-12-31 |
| CashCashAndCashEquivalentsAtCarryingValue | $222M | +190.7% | FY20252025-12-31 |
| Long-term debtLongTermDebt | $0 | −100.0% | FY20252025-12-31 |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Reported since the last full year
Three-month figures this company has filed since FY2025. A quarter is not comparable with a full year, and these figures are used nowhere else on the site: not in any ranking, not in comparisons, not in the download.
| Quarter | Revenue | Net income | Source |
|---|---|---|---|
| Q1 20262026-03-31 | $78.0M | −$3.0M | Open → |
| Q2 20262026-06-30 | $87.8M | $5.3M | Open → |
Only periods that end on a calendar quarter appear here. A company whose fiscal year ends in June files on a different calendar, so it has no row.
Profile
- Legal name
- Omada Health, Inc.
- Ticker
- OMDA
- Exchange
- Nasdaq
- SIC classification
- Services-Health Services (8000)
- Fiscal year end
- 12-31
- CIK
- 0001611115
Filings
- 10-QAug 7, 2026Open filing →
- 10-QMay 8, 2026Open filing →
- 10-KMar 6, 2026Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| Iovance BiotherapeuticsIOVA | $264M | −$391M |
| Jushi HoldingsJUSH | $263M | −$68.6M |
| ArvinasARVN | $263M | −$81.0M |
| Omada HealthOMDA | $260M | −$12.8M |
| SchrodingerSDGR | $256M | −$103M |
| Lemaitre VascularLMAT | $250M | $57.7M |
| Arcus BiosciencesRCUS | $247M | −$353M |
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Omada Health — Key figures |url=https://companiesranked.com/en/company/omada-health |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Omada Health — Key figures. CompaniesRanked. https://companiesranked.com/en/company/omada-healthBibTeX
@misc{companiesranked-en-company-omada-health-2026,
author = {{CompaniesRanked}},
title = {{Omada Health — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/omada-health}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0001628280-26-015637 · March 6, 2026
{{cite web |title=Omada Health — Key figures — 10-K (0001628280-26-015637) |url=https://www.sec.gov/Archives/edgar/data/1611115/000162828026015637/omda-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-03-06}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.